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SUMMARY 
 
BACKGROUND: Upper tract urothelial carcinoma (UTUC) accounts for 5-10% of all 
urothelial tumors. It is mostly diagnosed at advanced stages, entailing a worse 
prognosis, owing to the lack of early and specific symptoms as well as of 
effective diagnostic tools. 
 
AIMS: We previously identified a panel of epigenetic biomarkers (GDF15, TMEFF2 
and VIM promoter methylation) that accurately identifies bladder cancer in urine. 
Herein, the main aims of this Thesis were to assess the performance of the same 
panel for UTUC detection and prognosis, in tissue and urine, and to investigate 
its relevance in the urothelial carcinogenesis processes.  
 
MATERIAL AND METHODS: Methylation levels of reference and target genes were 
determined using real-time quantitative MSP in bisulfite-modified DNA of 57 
UTUC tissues, 36 normal upper tract urothelium (NUTUs), 22 urines from UTUC 
suspects and 20 urines from controls.  
ROC-curve analysis was performed to determine the performance of the 
biomarker panel and survival analyses were conducted to evaluate their 
prognostic value. 
Quantitative gene expression analysis, western blot and ChIP were performed to 
evaluate VIM deregulation in transitional cell lines exposed to DAC and TSA. 
 
RESULTS: Methylation levels of GDF15, TMEFF2 and VIM were significantly higher 
in UTUC compared to NUTUs (P = 0.022; P < 0.001; P < 0.001, respectively). The 
panel accurately identified UTUC with 100% and 91% sensitivity, corresponding to 
an area under the curve of 1.000 and 0.923 in tissue and urines, respectively, 
with 100% specificity. Low VIM promoter methylation levels independently 
predicted poor disease-specific survival. 
VIM transacript and protein levels increased after exposure to DAC, and for the 
same conditions, it was observed an increase of deposition of histone activation 
marks, with concomitant decrease of a repressive mark.  
 
CONCLUSIONS: GDF15, TMEFF2 and VIM promoter methylation allows for accurate 
identification of UTUC, in tissue and urine, and VIM methylation provide relevant 
prognostic information, especially in high-stage disease. Because UTUC 
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difficult to detect clinically and imagiologically at an early stage, this gene panel 
might provide a useful tool for early detection of UTUC in urine samples, and 
improve the clinical management of UTUC patients. Moreover, we confirmed that 
VIM is epigenetically regulated in transitional carcinoma cell lines, namely 
through the interaction of promoter DNA methylation and histone post-
translational modifications. 
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RESUMO 
 
INTRODUÇÃO: 5 a 10% de todas as neoplasias uroteliais são devidas ao carcinoma 
urotelial do trato urinário superior (UTUC). Este ultimo é sobretudo diagnosticado 
em estádios avançados de doença, tendo assim um pior prognóstico, muito 
devido ao facto de os principais sintomas serem praticamente nulos em estádios 
iniciais da doença, e também pela falta de testes de diagnóstico realmente 
eficazes.  
 
OBJECTIVOS: Recentemente, o nosso grupo de investigação identificou um painel 
de biomarcadores epigenéticos (a metilação dos promotores de GDF15, TMEFF2 e 
VIM) que detecta carcinoma urotelial da bexiga, tanto em amostras de tecido 
como em amostras de urina. Assim, os principais objectivos desta Tese 
consistem em avaliar, em tecidos e urinas, a utilidade deste mesmo painel na 
detecção e prognóstico de UTUC, e investigar a sua relevância nos processos 
carcinogénese urotelial. 
 
MATERIAL E MÉTODOS: Os níveis de metilação dos genes alvo e de referência foram 
determinados através de PCR quantitativo de metilação em tempo real  utilizando 
57 amostras de DNA de tecidos provenientes de UTUC, 36 amostras de urotélio 
normal do trato urinário superior (NUTU), 22 urinas provenientes de doentes 
suspeitos de UTUC, e 20 urinas de controlos.  
Foi realizada uma análise das curvas ROC para determinar a performance do 
painel de biomarcadores, bem como análises de sobrevivência para avaliar o seu 
respectivo valor prognóstico. 
Adicionalmente, foram também realizadas análises quantitativas de expressão 
génica, western blot e ChIP para avaliar a desregulação da VIM em linhas 
celulares de carcinoma transicional expostas aos agentes DAC e TSA. 
 
RESULTADOS: Os níveis de metilação do GDF15, TMEFF2 e VIM estavam 
significativamente aumentados nos UTUC quando comparados com os NUTU ((P = 
0.022; P < 0.001; P < 0.001, respectivamente). O mesmo painel conseguiu 
identificar UTUC em tecidos e urinas com uma sensibilidade de 100% e 91%, 
respectivamente, correspondente a uma área sob a curva de 1.000 e 0.923, e 
com uma especificidade de 100%. Os baixos níveis de metilação do promotor do 
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VIM foram igualmente identificados como marcadores independentes de mau 
prognóstico. 
Os níveis de transcrito e proteína da VIM aumentaram significativamente após a 
exposição à DAC, e para as mesmas condições, foi observado um aumento da 
deposição de marcas ativadoras das histonas, com concomitante decréscimo de 
uma marca repressora.  
 
CONCLUSÕES: A metilação dos promotores de GDF15, TMEFF2 e VIM permite a 
identificação de UTUC, tanto em tecidos como em urinas, fornecendo informação 
relevante sobre o prognóstico, principalmente para os estádios mais avançados.  
Devido às dificuldades na detecção clinica e imagiológica em estádios iniciais da 
doença, este painel de genes poderá constituir um importante método auxiliar de 
diagnóstico precoce de UTUC em amostras de urina, com um previsível impacto 
na decisão clínica.  
Finalmente, foi possível confirmar que o promotor do gene VIM é regulado 
epigeneticamente, havendo uma interação entre a metilação do DNA e as 
modificações pós-transducionais das histonas.  
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INTRODUCTION 
 
1. Epigenetics 
 
In 1941, C. H. Waddington coined the term Epigenetics referring to the 
study of the “causal mechanisms by which the genes of the genotype bring about 
phenotypic effects [1], years before DNA was identified as the molecule of 
inheritance by Watson and Crick. That definition suffered an evolution since then, 
and nowadays suits better in the field of developmental biology. If we search for 
the etymological meaning of the word, we found that the Greek prefix epi- in 
epigenetics implies features that are "on top of" or "in addition to" genetics; thus 
epigenetic traits exist on top of / in addition to the traditional molecular basis for 
inheritance. The actual definition of Epigenetics is now less focused on genotype, 
and more related to mechanisms that controls gene expression in a potentially 
heritable way, with no change in the primary DNA sequence [2, 3]. 
 
1.1. Epigenetic Mechanisms 
 
Epigenetic changes are preserved when cells divide. Most epigenetic 
changes only occur within the course of one individual organism's lifetime, but, if 
gene deactivation occurs in a sperm or egg cell that results in fertilization, then 
some epigenetic changes can be transferred to the next generation [4]. 
As previously mentioned, epigenetic changes are capable of modifying the 
expression of certain genes, but not the DNA sequence itself; in addition, the 
chromatin proteins associated with DNA may be activated or silenced. Due to 
these phenomena, a multi-cellular organism can be comprised of several 
differentiated cells owing the same genetic sequence, but expressing only the 
genes that are necessary for their own activity. The concept of Epigenome fits in 
these findings: having a group of molecular mechanisms that act together 
towards the regulation of what can and cannot be genetically accessed at a 
certain point of the cell maturation, and therefore contributing together with the 
genetic information for the phenotype of each cell [5].  
These so called epigenetic molecular mechanisms may be grouped into 
three major categories: DNA methylation, histone post-translational modifications 
and RNA-associated transcriptional silencing (Figure 1).  
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In addition to these, many other epigenetic mechanisms have been 
studied, such as histone variants, ATP-dependent chromatin remodeling 
complexes and polycomb/trithorax protein complexes [6, 7]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Different types of epigenetic information. DNA methylation, histone 
modifications, and RNA-mediated gene silencing constitute three distinct 
mechanisms of epigenetic regulation. (Adapted from [8]) 
 
 
1.1.1. DNA methylation 
 
Cytosine DNA methylation, the most studied of epigenetic changes, is a 
covalent modification of DNA, in which a methyl group (CH
3
) is transferred from 
S-adenosylmethionine (SAM) to the fifth carbon (C-5) of cytosine by a family of 
(DNA-5)-methyltransferases (DNMTs), resulting in a new DNA base - 5- 
methylcytosine (m5C) (Figure 2). This specific DNA base accounts for ~1% of all 
bases, varying slightly among different tissue types, and corresponding to 3-6% 
of all cytosines [9] and 70-80% of all CpG dinucleotides [10]. CpG sequences are 
underrepresented in the genome owing to the evolutionary trend for depletion of 
such dinucleotides due to spontaneous deamination of m5C into thymine (T) and 
the failure of recognition by the mismatch repair mechanism [11-13]. 
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Figure 2. Reaction catalyzed by DNMTs. Addition of a methyl group to the 
cytosine ring resulting in a 5-methylcytosine using SAM as the methyl donor. (Adapted 
from [14]) 
 
DNA methylation occurs almost exclusively at CpG dinucleotides and has 
an important role in the gene expression regulation and in the silencing of repeat 
elements in the genome [15]. Across the genome we often find clustered regions 
of CpG dinucleotides, also known as CpG islands, defined as regions of more 
than 200 bases with a G+C content of at least 50% and a ratio of observed to 
statistically expected CpG frequencies of at least 0.6 [16]. It is estimated that 
approximately 60% of human gene promoters contain CpG islands [11] and are 
normally unmethylated in the majority of cells, corresponding to the maintenance 
of an open chromatin structure and a potentially active state of transcription [17]. 
However, some conditions require a change in the gene-promoter unmethylated 
to methylated status, such as in some imprinted genes, X-chromosome genes in 
the female gender [18] and in tissue and germline specific genes [19]. 
In human cells, three major DNMTs are responsible for DNA methylation. 
Methylation patterns are maintained by DNMT1, which preferentially methylates 
hemi-methylated DNA (e.g., duplex DNA in which only one of the strands is 
methylated) following DNA replication. DNMT3A and DNMT3B are known as the 
de novo methyltransferases. Although DNMT3A and DNMT3B show no preference 
for unmethylated DNA over hemi-methylated DNA, the low level of the de novo 
methylation carried out by DNMT1 relative to DNMT3A and DNMT3B have led to 
the later two enzymes being designated as the de novo methyltransferases [20, 
21]. The DNA methyltransferases family includes another two members: DNMT2 
and DNMT3L. DNMT2 is the smallest mammalian DNA methyltransferase and it 
shows reduced methyltransferase activity [20, 22]. DNMT3L is a DNMT-related 
protein, which does not have a methyltransferase activity. Instead, it interacts 
with de novo DNA methyltransferases, and appears to have an important role in 
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imprinting, namely in maternal imprinted genes [6, 9, 20]. Changes in the 
expression of the DNMTs are a contributing factor to changes in methylation 
patterns. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Chromatin structure of active and inactive promoters. A) 
Transcriptionally active chromatin is characterized by unmethylated cytosines and 
acetylated histone tails. B) Transcriptionally silenced chromatin is characterized by 
methylated cytosines and desacetylated histone tails. (Adapted from [14]) 
 
As previously mentioned, DNA methylation interferes directly with gene 
expression by obstructing the action of transcription activators on methylated 
regions in or near the promoter (Figure 3A). In addition to this, another 
mechanism by which DNA methylation can indirectly regulate transcription is 
through the recruitment of DNA methyl-binding proteins containing methyl-CpG-
binding domains (MBD). These regions contained in proteins such as MeCP1 and 
MeCP2 include amino acid residues capable of binding to methylated DNA. There 
are currently several proteins that have been identified and that are referred to as 
MBD proteins (MBPs), which have the capacity to silence transcription by binding 
to both hemi-methylated and fully methylated DNA [20, 23]. They act towards the 
recruitment of transcriptional co-repressors such as histone deacetylating 
complexes, polycomb proteins, and chromatin remodeling complexes, and attract 
chromodomain-binding proteins (Figure 3B).  
Herein, two of the most studied examples of the importance of natural 
CpG island methylation for the normal development of mammalian cells are the 
inactivation of one of the X chromosomes in females and the imprinted genes. 
The first is responsible for the maintenance of stable long-term random 
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transcriptional silencing of one of the X chromosomes in the female gender, 
leading to gene-dosage compensation [6, 24, 25]; whereas the second is a non-
Mendelian inheritance phenomenon [26], by which one of the parental alleles of a 
gene becomes transcriptionally silenced, in male or female germlines, leading to 
monoallelic expression in progeny in a parent-of-origin specific manner [6, 26].  
The spontaneous and natural occurrence of DNA methylation not only 
occurs in the course of cell early development, but also is an integral part of 
aging and cellular senescence. It is known that the overall content of cytosine 
methylation decreases with age, while other genes acquire methylation at their 
promoters, a phenomenon which resembles the methylation changes that are 
found in cancer [27].  
DNA methylation plays an important role in the maintenance of genome 
integrity by transcriptional silencing of repetitive genomic regions, such as those 
of pericentromeric regions, transposons (DNA sequences that are able to move 
across the genome), and inserted viral sequences [28]. In fact, these regions are 
naturally densely methylated, which in this case comprises a protective effect 
against chromosomal instability and potentially deleterious recombination events 
between non-allelic repeats caused by these mobile genetic elements [29]. In 
addition, as previously stated, methylation increases the mutation rate of m5C to 
T, leading to a faster divergence of identical sequences and disabling of many 
retrotransposons [6]. 
 
 
1.1.2. Histone Post-Translational Modifications 
 
Nucleosomes are the basic units that compose the chromatin fiber. In 
eukaryotes, each of these primary building units consists of four core histones 
(H3, H4, H2A and H2B), which form a histone octamer, assembled from two 
heterodimers of H3 and H4 with two heterodimers of H2A and H2B. Wrapped to 
the histone octamer are 146 base pairs of DNA, thereby forming the complete 
structure of the nucleosome. Another histone, H1, binds to DNA between 
nucleosomes, and this structure is twisted and folded in highly ordered and 
compacted chromatic filaments [30]. Not so long ago, histones were thought to 
be static elements, which only function comprised the DNA packing; however, 
these proteins are currently considered key players in epigenetics, as explained 
below.    
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Figure 4. Most frequent post-translational modifications in human histone 
“tails”: A - acetylation; M - methylation; P - phosporylation; U - ubiquitination. (Adapted 
from [31]) 
 
The histone proteins contain a globular C-terminal domain and an 
unstructured N-terminal tail [32], being the last a target to various residue-
specific post-translational covalent modifications, such as acetylation, 
methylation, phosphorylation, ubiquitylation, sumoylation, and ADP ribosylation 
(Figure 4) [33]. These histone modifications have important roles in various 
cellular mechanisms, as in transcriptional regulation, DNA repair [34], DNA 
replication, alternative splicing [35] and chromosome condensation [33], by 
unwrapping nucleosomal DNA or sliding nucleosomes along it, allowing the 
protein machinery to access the DNA sequence.  
The concept of the “histone code” arises by the establishment of different 
combinatorial patterns of post-translational modifications in different residues of 
each one of the nucleosome core histones. Once read out by other proteins, this 
code is responsible by determining the structure and activity of different 
chromatin regions, being more or less stable accordingly to the cell environment 
stimuli [36-38].   
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The acetylation and methylation status of specific lysine residues 
contained within the tails of nucleosomal core histones is known to play a critical 
role in regulating chromatin structure and gene expression. 
Lysine acetylation is a reaction catalyzed by histone acetyltransferases 
(HATs), and is commonly associated with transcriptional activation, whereas the 
reverse reaction, performed by histone deacetylases (HDACs), leads to a negative 
gene expression regulation [33]. The above-mentioned transcriptional activation 
due to acetylation happens because it partially neutralizes the positive charge of 
histones, weakening their interaction with the nucleosomal DNA, thereby 
facilitating the access of transcription factors to their recognition element. 
Additionally, acetylation helps gene transcription by creating a specific signal for 
regulatory factors or chromatin-remodeling complexes, contributing to their 
targeting to a specific region [39, 40]. The dynamic equilibrium between HATs 
and HDACs regulates the overall histone acetylation status [41]. 
Methylation as a histone post-translational modification is substantially 
different from acetylation: it may occur at lysines and arginines; histone lysines 
can become mono-, di-, or trimethylated, whereas arginines may only be mono- 
or dimethylated (symmetrically or asymmetrically); it does not alter the histone 
tails charge; and it has been implicated in both transcriptional activation and 
repression, depending on the altered residue, its position, and its histone code 
context [40, 41]. For example, open chromatin is characterized by trimethylation 
of lysines 4, 36 and 79 of H3 (H3K4me3, H3K36me3 and H3K79me3), while 
heterochromatin features high monomethylation levels of lysines 9 and 27 of H3 
(H3K9me and H3K27me), and lysine 20 of H4 (H4K20me) [42]. The effectors of 
these operations are the histone methyltransferases (HMTs), which catalyze the 
addition of a methyl group to histone residues using SAM as a cofactor, and 
display higher substrate specificity when comparing with HATs and HDACs [43]. 
Together with the HMTs, the histone demethylases (HDMs) are the answer of how 
histone methylation can regulate transcription and enable gene maintenance in 
an on or off state [40].  
Overall, these histone modifiers generally act together in complexes, such 
as the repressive Polycomb (PcG) and activating Trithorax (TrxG) group 
complexes, which counterbalance each other in gene regulation [44].  
In normal mammalian cells, histone hypoacetylation and hypermethylation 
are characteristic of DNA sequences that are naturally methylated and repressed 
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– such as in the previously mentioned inactive X chromosome in females, and 
silenced imprinted and tissue-specific genes [45]. 
 
 
1.1.3. MicroRNAs 
 
MicroRNAs (miRNAs) are an evolutionary conserved group of small RNAs 
(18-24 nucleotides) that are processed from much longer transcripts, by RNA 
polymerase III, and arise from hairpin structures after successive enzymatic 
maturation steps, performed by the sequential action of Drosha and Dicer 
endonucleases [46]. Following incorporation into the ribonucleoprotein complex 
RISC (RNA-induced silencing complex), the miRNAs bind mRNAs, primarily at their 
3’ untranslated regions (UTRs), through partial complementarity of their both 
sequences. Consequently, mRNA suffers decay and the translation is suppressed, 
leading to a reduction on protein levels. Moreover, recent reports showed that 
some miRNAs might also bind to the 5’ UTR of the target genes, functioning as 
transcription activators [46-48].  
The behavior of this class of molecules is considered somehow 
promiscuous, because each miRNA has many targets and the individual mRNAs 
can be targeted by multiple miRNAs [49]. Actually, nowadays miRNAs are 
considered one of the most important groups of gene regulatory molecules, by 
controlling a wide range of biological processes, such as differentiation, 
proliferation, and apoptosis. A connection between epigenetics and miRNAs has 
been sustained by the recent identification of the “epi-miRNAs” specific subgroup, 
which can directly and indirectly modulates the activity of the epigenetic 
machinery [50]. 
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2. Cancer: a Global Threat  
 
Cancer has been the main concern of many life sciences researchers and 
medical doctors worldwide, as it affects all kind of people of all ages and social 
status. The term Cancer was first described by Hippocrates, in the ancient 
Greece, and the oldest known description and surgical treatment of cancer was 
discovered in Egypt and dates back to approximately 1600 BC. Cancer is not one 
disease but rather a large and heterogeneous group of diseases that share 
similar attributes: the cells show uncontrolled growth as a result of mutations 
that affect a limited number of genes. In the past century, with the discovery of 
the main molecular mechanisms of the cells, we now know that the carcinogenic 
process confers selective growth advantages (e.g., evasion of apoptosis and 
metastasis formation) to the tumor, and gives rise to its proliferation, invasion, 
dissemination, and drug resistance traits [51]. 
Most cancers are collections of phenotypically mixed cell populations with 
variable proliferative potential, a feature shared with normally developing organs. 
Two primary models have gained support to account for this variability. The 
clonal evolution model proposes that multiple genetic mutations confer upon a 
cell the ability to proliferate indefinitely, and that a subsequent mutation will 
confer a growth advantage upon one of this cell’s progeny. The new, more 
rapidly growing clone will outcompete other clones and dominate the tumor [52, 
53]. The cancer stem cell model provides an alternative explanation, assigning 
cellular heterogeneity to differing degrees of differentiation. According to this 
model, heterogeneity is predictable rather than random, recapitulating aspects of 
the developmental and homeostatic mechanisms of normal tissues. 
 
 
 
2.1. Epigenetic Modifications in Cancer 
 
Recent advances in the field of Epigenetics have shown that human cancer 
cells, in addition to the previously mentioned genetic alterations, harbor global 
deregulation of epigenetic events (so called “epimutations”). In fact, these 
epigenetic alterations may work as a trigger of neoplastic development, working 
together with genetic mutations to promote cancer progression [29]. Cancer is 
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now seen not only as a genetic based disorder, but also as an epigenetic disease, 
since epimutations are increasingly associated with the silencing of tumor-
suppressor genes (TSGs) and activation of proto-oncogenes [5, 54].  
With the progress that has been made in the study of different epigenetic 
mechanisms, an increased knowledge of how these mechanisms may influence 
malignant cellular transformation as been gathered, as detailed bellow.   
 
2.1.1. DNA Methylation in Oncogenesis 
 
Cancer initiation and progression is accompanied by deep variations in 
DNA methylation landscape. Indeed, a cancer cell is characterized by genome-
wide loss of m5C, contrasting with the subsequent hypermethylation of CpG 
islands, more precisely TSGs CpG island promoter methylation (Figure 5) [54, 55].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. DNA methylation changes in cancer: TSGs promoter hypermethylation 
and global genome-wide methylation loss. (Adapted from [5]) 
 
Global DNA hypomethylation was one of the first epigenetic alterations 
reported in cancer cells, more than three decades ago (Feinberg and Vogelstein, 
1983). In fact, it is known that a cancer cell features a loss of 20-60% of the total 
number of m5C when compared to a normal cell from the same tissue [13]. 
Moreover, it has been clearly established that hypomethylation occurs early in 
tumorigenesis and it is a feature of different types of human neoplasms (benign 
or malignant), increasing with disease progression [2, 56]. 
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This epigenetic change is mainly due to demethylation of repetitive DNA 
sequences, coding regions, and introns of genes. The consequences of the 
methylation loss of this particular sequences may represent: loss of imprinting 
[57]; generation of chromosomal instability, because demethylation of DNA can 
favor mitotic recombination, leading to deletions and translocations [58, 59]; re-
activation of transposons [60, 61]; and activation of normally methylated 
oncogenes [62]. Moreover, there are still several loose ends in the research 
regarding the effects of hypomethylation in cancer. 
On the other hand, the effects of hypermethylation in tumorigenesis are 
much better established and vastly studied, and there is strong evidence that this 
epigenetic alteration affects both malignant initiation and progression. Indeed, 
considering Knudson’s two-hit hypothesis for inactivation of TSG [63], in addition 
to a mutation or other genetic phenomena in one of the alleles, the other 
necessary event may well be the promoter aberrant methylation, therefore 
activating the tumorigenic mechanisms [64]. Alternatively, both alleles of a TSG 
may also become inactivated by this epigenetic event. 
Actually, it is acknowledged that the transcriptional inactivation caused by 
promoter hypermethylation affects genes involved in the main cellular pathways, 
such as in the promoters of MGMT and BRCA1 (involved in DNA repair), RB (cell 
cycle control), and WIF-1 and DAPK1 (apoptosis), among others [65]. The list of 
genes undergoing silencing through methylation in several different types of 
cancer is now very extensive, as the research in this particular field is increasingly 
sought.  
 
2.1.2. Histone onco-modifications 
 
While aberrant DNA methylation is the most extensively studied epigenetic 
change in cancer, recent discoveries have revealed that both deregulation of 
histone modifications and chromatin remodeling are also implicated in cancer. 
Moreover, it has become evident that DNA methylation and histone modification 
pathways can be dependent on one another, and that this cross-talk can be 
mediated by biochemical interactions between HMTs and DNMTs [66].  
If taken into consideration the previously discussed fundamental roles of 
histone modifications, it is not surprising that aberrations in histone 
modifications are discovered in cancer. These alterations may lead to mutations 
in oncogenes, TSGs or DNA repair genes resulting in genomic instability, 
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oncogenic transformation and the development of cancer [5]. Thus far, only a few 
of the total number of histones residues in which modifications have been 
described were linked to malignant transformation [33]. It is the example of 
global loss of acetylated H4K16, the trimethylation of H4K20, and the changes in 
methylation patterns of H3K9 and H3K27, found in various forms of cancer [67].  
In addition, several of the histone-modifying enzymes have also been 
described to be altered in cancer cells [56]. HDACs are frequently found 
overexpressed in several types of cancer, and HATs, which work together with 
HDACs to preserve histone acetylation levels, may also be altered in those 
situations [68]. Similarly, deregulation of HMTs results in altered distribution of 
histone methylation marks in cancer, such as EZH2 (the H3K27 HMT) that is often 
found overexpressed in breast and prostate cancer [69].  
Additionally, it is currently known that the incorporation of specific histone 
variants is altered in cancer cells. In fact, various researchers are focusing their 
efforts in understanding how this alternative histones influence tumorigenesis, as 
in the example of a 2011 study in which the authors showed that during 
sequential development of hepatocellular carcinoma, the histone variants H2A 
and H2A.1 were overexpressed, whereas H2A.2 had decreased [70]. 
 
2.1.3. MicroRNA Deregulation in Cancer 
 
Firstly identified in B-cell chronic lymphocytic leukaemia (CLL) [71], 
changes in the expression levels of miRNAs have been successively found by 
different authors in many types of human neoplasms.  
MiRNAs have been proposed to contribute to oncogenesis since their 
function implies regulation of genes involved in transcriptional regulation, cell 
proliferation and apoptosis, and aberrant expression of those miRNAs favors 
tumorigenesis. Importantly, miRNAs can function either as tumour suppressors 
(as is the case for miR-15a and miR-16-1) or oncogenes (as is the case for miR-
155 or members of the miR-17–92 cluster), depending upon their target genes 
[72].  
This miRNAs expression deregulation may occur as a consequence of 
amplification, deletion, mutation, chromosomal abnormalities, changes in 
expression of transcription factors and gene promoter methylation [73, 74]. 
Indeed, those miRNAs with tumor suppressor features could undergo aberrant 
DNA methylation accompanied by histone modifications associated with 
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transcriptional inactivation. Several studies have been made to support this 
hypothesis, namely a recent report showed that breast cancer cells treated with 
histone deacetylase inhibitors (HDACi) display an extensive and rapid alteration 
of miRNA levels [75].  
 
 
2.2. Epigenetic Therapy 
 
The dynamic nature and potential reversibility of DNA and histones 
modifications renders them as appealing therapeutic targets in cancer 
intervention. Indeed, the aim of this so called epigenetic therapy is to reverse the 
causal epigenetic abnormalities that arise in cancer, leading to the reinstatement 
of a normal epigenome landscape [76]. 
Multiple therapies have been tested over the past decade to treat neoplasia 
through demethylation of DNA. Most of those therapies reduce methylation 
through DNMTs inhibitors (DNMTi). One class of compounds handed as 
demethylation agents are nucleoside analogues. They have a structure similar to 
that of cytosine and when incorporated into DNA they will covalently bind DNMTs 
to the DNA. The DNMTs will then remain bound to the DNA preventing them from 
carrying out methylation elsewhere. Examples of these compounds are 
azacytidine, zebularine and decitabine. Remarkably, the FDA has approved the 
use of two such agents, 5- azacytidine and 5-aza-2′-deoxycytidine (DAC), as 
elective treatments for myelodisplastic syndrome [76]. Other molecules such as 
Genistein, procainamide, antisense oligonucleotides and siRNAs have all been 
shown to reduce hypermethylation. 
Not only DNMTi have shown promising results in cancer fight front, but 
also the HDAC inhibitors (HDACi), which have demonstrated antitumor, growth 
inhibitory, proapoptotic, and prodifferentiation properties [77]. These 
antiproliferative properties of HDACi are mediated by their ability to reactivate 
TSGs, and because of that there is intense trial activity regarding these 
compounds [78]. Actually, suberoylanilide hydroxamic acid was the first drug of 
this type approved by the FDA for the treatment of cutaneous T-cell lymphoma 
[76, 79], and more recently romidepsin showed great improvements in the 
treatment of the same condition, being also approved by FDA in 2009 [80]. 
Another HDACi, Trichostatin A (TSA), has been tested in vitro and it was 
demonstrated that its activity may lead to apoptosis, as well as differentiation 
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and cell-cycle arrest [81]. Moreover, several other molecules are being tested in 
clinical trials. 
A schedule-dependent synergistic effect between DAC and TSA has already 
been tested by various groups, and resulted in to the re-expression of previously 
methylated promoters, emphasizing the complementarity/interaction between 
the different epigenetic gene regulation mechanisms [82, 83]. 
 
 
2.3. Cancer Biomarkers: The Epigenetics contribution 
 
There is a great need for novel methods able to detect cancer at an early 
stage. Evaluation of molecular changes in tumor cells might be a useful ancillary 
tool for the existing detecting methods in the early detection of various types of 
cancer, specifically of urological cancers [84]. 
A cancer biomarker is any biological substance that is indicative of the 
presence of the tumor in the body. It can be derived from the tumor site, remote 
media or found in circulation. These biomarkers include cell-free tumor derived 
DNA, RNA, and protein.  
In addition, epigenetic changes, including DNA methylation, have been 
used to detect cancer. Owing to their chemical and biological stability, DNA 
methylation-based biomarkers have potential clinical applications in cancer 
detection, diagnosis, and targeted therapies [85]. As previously mentioned, 
epigenetic changes, associated with loss of gene expression, are common events 
in cancer, and hypermethylation is the most studied of all. The finding that DNA 
methylation is an early occurrence in cancer coupled with the chemical and 
biological stability of this alteration makes it a potential diagnostic tool for cancer 
[86]. 
DNA methylation assays can be performed on small biopsy samples 
obtained during the routine diagnostic work-up of patients, on archived frozen or 
paraffin-embedded tissue, as well as on the soluble genomic DNA found in the 
peripheral blood and other fluids of many cancer patients, offering the possibility 
of non-invasive molecular screening for many malignancies [87]. 
The efficacy of a biomarker assay is determined by its sensitivity and 
specificity. Clinical sensitivity of a biomarker is determined by the ratio of cancer 
cases that test positive among the total number of cases tested. Specificity is 
assessed by the number of healthy individuals that test negative for the particular 
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biomarker. In this process of biomarker selection, it is also important to consider 
other factors that influence gene methylation. Since DNA methylation aberrations 
are affected by factors such age, race, diet, and stage of disease, it is important 
to analyze gene methylation data by taking these variables into consideration 
[86]. 
 
 
2.4. GDF15, TMEFF2 and VIM  
 
In a previous work of our group [88], a panel of three epigenetic 
biomarkers – GDF15, TMEFF2 and VIM – was identified for accurate identification 
of urothelial carcinoma of the bladder. 
The GDF15 gene, located at 19p13.11, encodes a divergent member of the 
transforming growth factor (TGF)-β superfamily, which is a large family of 
secreted molecules required for normal development, differentiation, and tissue 
homeostasis. It has been postulated that, like other members of the TGF-β 
superfamily, GDF15 might act as tumor suppressor in early cancer stages and as 
a pro-tumorigenic at later stages of tumor progression [89].  
The TMEFF2 gene, located at 2q32.3, encodes a transmembrane protein 
with EGF-like domains and two follistatin-like domains, involved in cell 
proliferation control. The VIM gene, located at 10p13, encodes the intermediate 
filament Vimentin. Both TMEFF2 and VIM had previously found to be silenced 
through aberrant promoter methylation in esophageal, gastric and colon cancer 
[90-94].  
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3. Upper Urinary Tract Urothelial Cell Carcinoma 
 
3.1. Upper Urinary Tract: Anatomical Insights 
 
The human urinary tract may be distinguished between upper and lower 
segments. The upper tract includes the renal pelvis and the ureters, and the 
lower tract comprises the bladder and urethra. Specifically, the ureters are 
hollow, muscular tubes that carry urine from the kidneys to the bladder, and the 
renal pelvis is the lower part of each kidney that connects to each ureter (Figure 
6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Anatomy of the human upper urinary tract. (Adapted from [95]) 
 
Urothelium, from which all the urothelial tumors originate, is a highly 
specialized epithelium, which covers most of the urinary tract. Situated 
strategically between the urine and blood, normal urothelium acts as a 
physiologically effective and mechanically flexible permeability barrier that on the 
one hand protects the underlying tissues from toxic urinary substances and on 
the other hand adjusts its surface area actively and reversibly during the 
micturition cycle [96]. 
 
3.2. Epidemiology of Upper Tract Urothelial Cancer 
 
Urothelial cell carcinomas (also known as transitional cell carcinomas) are 
the fourth most common tumors worldwide after prostate (or breast), lung 
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cancer, and colorectal cancer [97, 98]. However, Upper Tract Urothelial 
Carcinomas (UTUCs) are uncommon and account for about 7% of renal 
neoplasms, and only 5 to 10% of all urothelial cell carcinomas. Moreover, the 
estimated annual incidence of UTUCs in Western countries is about two new 
cases per 100 000 inhabitants [97, 99]. However, despite presenting more rarely, 
most UTUCs (60%) are invasive at diagnosis, in contrast to the 15-25% in bladder 
urothelial carcinoma [100].  
These tumors have a peak incidence in the seventh decade, and they are 
three times more prevalent in adult males than in females [101]. However, as is 
the case with bladder cancer (BlCa), women who develop UTUC are 25% more 
likely than men to die of their disease [99, 102].  
 
3.3. Classification and Staging 
 
In the past few years, with the advance in the knowledge of the molecular 
basis of UTUCs, the World Health Organization (WHO) changed its classification 
based on a grade scale to a more suitable classification that better show the 
natural evolution of these tumors, and takes into consideration histological 
insights. Moreover, these tumors are usually classified as low-grade papillary 
urothelial carcinoma, high-grade papillary urothelial carcinoma and high-grade 
invasive urothelial carcinoma, according to 2004 WHO classification. In addition, 
UTUC also follow the TNM stage classification of malignant tumors, which assess 
tumor size, lymph node involvement, and distant metastasis (Table 1) [103]. 
 
Table 1. TNM classification of carcinomas of the renal pelvis and ureter. (Adapted 
from [103] 
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3.4. Risk Factors 
 
Presently, there are several environmental risk factors that are known to 
influence the development of UTUCs, and the great majority of them are shared 
with BlCa, with few exceptions. Among them, tobacco smoke, occupational 
exposure to aromatic amines, and the Balcan endemic nephropathy remain the 
best established, as explained bellow [104].  
The association of urothelial carcinogenesis with smoking exposure is 
complex and linked to multiple inhaled toxic substances, as the example of 
aromatic amines. The mechanism of action includes its metabolization into N-
hydroxyalanine, which is proven to have a real carcinogenic activity. The relative 
risk (RR) of developing UTUC under tobacco exposure increases 2.5–7, 
comparative with non-smokers [105]. This risk is modulated by the number of 
years of exposure and by the number of cigarettes smoked every day. 
Occupational exposure to aromatic amines can also lead to the 
development of UTUC. These aromatic hydrocarbons are used in many industries 
(eg, dyes, textiles, rubber, chemicals, petrochemicals, and coal). Benzidine and b-
naphthalene are two known chemicals that belong to this family, and have a 
documented carcinogenic potential. Precisely because of that, these two 
chemicals have been banned since the 1960s in most industrialized countries. 
Yet about occupational exposure, researchers found that the developing of UTUC 
only occurs after an average duration of exposure of approximately seven years, 
and that the estimated risk (odds ratio) of developing UC after exposure to 
aromatic amines is 8.3 [104, 106].  
Another well-known risk factor for the developing of UTUC is the Balcan 
endemic nephropathy (BEN). BEN is described as a proximal tubular dysfunction 
responsible for the presence of a low molecular weight protein and a dense 
interstitial fibrosis within the glomeruli, and is intrinsically associated with UTUC, 
in the rural areas of the Balkans. The evidences indicate that this association is 
due to the consumption of chinese herbal products containing Aristolochia 
fangchi (a plant endemic to the Balkans) [107, 108]. Its mechanism of actions 
causes a specific mutation in the p53 gene at codon 139. This mutation is very 
rare in the non-exposed population and predominant in patients with 
nephropathy due to Chinese herbs or BEN that present with UTUC.  
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3.5. UTUC Diagnosis and Prognosis Assessment  
 
3.5.1. Diagnosis and Treatment 
 
The type and severity of clinical signs and symptoms of UTUCs depends on 
the extent and location of the tumor. The most common first presenting 
symptom is microscopic hematuria, although most tumors are clinically silent 
until they reach advanced disease stages. 
Nowadays, the diagnostic approach for UTUC is through CT-urography, 
cystoscopy and urinary cytology, and the gold standard treatment for those 
tumors is open radical nephroureterectomy (RNU) [99]. Endoscopic management, 
however, is also a reasonable therapeutic option in selected patients (Figure 7). 
Some new diagnostic approaches have been tested in the past few years, such as 
the use of nomograms [109] and fluorescence in situ hybridization [110]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Proposed flowchart for the management of UTUC. (Adapted from [99]) 
 
Because of the current invasive diagnostic and treatment techniques, 
UTUCs are optimal candidates for the previous mentioned biomarkers approach, 
as it would aid in their early detection and assessment of prognosis. 
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3.5.2. Prognostic Factors 
 
There are several factors that determine the decisions made by clinicians 
in diagnose and management of UTUC.  
As expected, the more important prognostic factors for UTUC progression 
are the tumor stage and grade, as well as the location of the primary tumor 
within the upper tract (eg, ureter vs. renal pelvis), being the ureteral tumors 
those with worst outcome [111, 112]. Other factors such as tumor necrosis, 
surgical margins of the resected tumor, and lymphovascular invasion, are also 
taken into consideration.  
Additionally, patients’ age is also taken into consideration, because older 
age at the time of RNU is associated with decreased cancer-specific survival [113]. 
Nonetheless, when the addition of age in a model that includes standard 
pathological features for prediction of disease recurrence did not alter or improve 
the predictive accuracy of the same, it was established that RNU should not be 
denied to elderly patients [114].  
 
3.5.3. Molecular Markers 
 
The most studied factors for assessing the biomarker potential of UTUCs 
are proteins involved in phenomena such as cell adhesion, angiogenesis, cell 
proliferation, apoptosis and cell-cycle regulation. Table 2 shows a review of the 
most studied UTUC markers until today.  
It has been reported that the expression profiles of E- cadherin and N-
cadherin, particularly the gain of N-cadherin expression, were significantly 
associated with disease recurrence after RNU in UTUC [115]. It can be used in a 
group of patients that require a thorough follow-up. Also, the expression of 
hypoxia-inducible factor 1α, a protein involved in angiogenesis, more specifically 
in cell hypoxia adaptation, has shown association with UTUC recurrence and 
overall mortality. Moreover, it was associated with grade, pattern of growth, but 
not with stage, and it was undetectable in normal urothelium [116]. Similarly, Ki-
67 protein, which is a known marker of cell proliferation, has been found to 
correlate with tumor grade and stage [117].  In fact, several studies suggest that 
high Ki-67 index is indicative of a worse prognosis. 
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Table 2. Summary of the main markers of interest in UTUC. (Adapted from [113]) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, UTUC tumors with metaplastic differentiation have been 
demonstrated to be more resistant to chemotherapy. Recent studies suggested 
that the epidermal growth factor receptor (EGFR) expression is associated with 
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advanced disease and metaplastic differentiation, having a potentially significant 
prognostic value in this particular type of tumor [118]. Recently, in a series of 82 
UTUC cases, the tumors overexpressing EGFR were of high-grade and this event 
may be of interest for targeted therapy [119].  
Telomerase has been found to be reactivated in most human cancer tissue 
but repressed in normal somatic tissues. To investigate the use of telomerase as 
a marker in UTUC, telomerase RNA component (hTR) overexpression detected by 
in situ hybridization has been identified as an independent prognostic marker of 
both UTUC recurrence and survival. Moreover, hTR was suggested for UTUC 
diagnosis, as it was detected in most cases of these tumors [120].  
UTUC has also been associated with tumors exhibiting microsatellite 
instability, a phenomenon where microsatellite regions of DNA get longer or 
shorter (e.g. expansion or deletion) owing to mutations in genes that repair 
damaged DNA. These alterations can be easily detected in exfoliated urine by 
PCR amplification with DNA from tumor and normal tissues, and has good overall 
sensitivity and specificity. Cases of UTUC have been linked to hereditary non-
polyposis colon cancer (HNPCC), a condition caused by a germline mutation in a 
mismatch repair gene, and with high MSI levels. Therefore, UTUC tumors with 
high MSI levels are classified as hereditary, and associated with HNPCC [121, 
122]. In addition, MSI can be also detected in ~25% of sporadic UTUC cases, and 
functions as an independent prognostic factor that could identify a subset of 
patients with a better prognosis [123].  
Moreover, back to the epigenetics, and knowing that a great percentage of 
UTUC has MSI, Catto and his colleagues observed that methylation can be the 
responsible for hMLH1 inactivation in those cases, and was associated with 
advanced tumor stage, suggesting that this group of tumors might benefit from 
the development of novel therapies with demethylating agents [124]. 
Due to the rarity of this disease, although there have been various studies 
investigating the diagnostic, and mainly, the prognostic value of several 
molecular biomarkers for patients with UTUC, most of them are single center, 
small in size and lack external validation. 
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AIMS OF THE STUDY 
 
This Master Thesis project was performed within the Cancer Epigenetics 
Group of the Research Center of the Portuguese Oncology Institute – Porto. In a 
previous work of our research team, a panel of three epigenetic biomarkers – 
promoter methylation of GDF15, TMEFF2 and VIM – was discovered to accurately 
identify bladder UC. Indeed, a 100% sensitivity and specificity was found in tissue 
samples, and 94% sensitivity and 100% specificity in urine samples [88]. Because 
bladder UC and UTUC display clinical and genomic similarities [125], we 
hypothesized that the same panel of biomarkers might be useful for non-
invasive, early detection of UTUC. Therefore, we used these previous findings to 
design the aims of this new project, which comes to live in this Thesis.  
 
 
 
Thus, the major aims of this study were:  
 
⇒ Evaluate the performance of quantitative GDF15, TMEFF2 and VIM 
promoter methylation in a consecutive series of tissue samples from 
UTUC; 
⇒ Determine the feasibility of detecting UTUC in voided urine samples 
suspicious of malignancy; 
⇒ Assess whether the panel of genes has prognostic value for this 
type of cancer; 
⇒ Explore the biological significance of VIM gene in the pathways of 
UTUC carcinogenesis using transitional carcinoma cell lines. 
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MATERIAL AND METHODS 
 
1. Clinical Samples 
 
1.1. Patients and tumor sample collection 
Fifty-seven UTUC samples were obtained from a consecutive series of 
patients diagnosed and treated with RNU or ureterectomy at the Portuguese 
Oncology Institute – Porto, Portugal, between 2000 and 2011, with no previous 
history of bladder cancer. Tissues were routinely fixed and paraffin-embedded for 
standard pathologic examination, allowing for tumor classification and WHO/ISUP 
grading [103], and staging [126]. Additionally, an independent set of 36 paraffin-
embedded normal upper tract urothelium (NUTU) from renal cell carcinoma 
patients was used as controls. Relevant clinical data was collected from clinical 
charts, and can be consulted in Table 3. 
  
Table 3 - Clinical and histopathological parameters of patients with UTUC and NUTU. 
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinicopathological 
features 
UTUC NUTU 
Patients, n 57 36 
Gender, n (%)   
Male 39 (68) 23 (64) 
Female 18 (32) 13 (36) 
Median age, yrs (range) 72 (52 - 85) 62 (49 - 82) 
Pathological stage, n (%)   
pTa 4 (7) n.a. 
pT1 22 (38) n.a. 
pT2 13 (23) n.a. 
pT3 17 (30) n.a. 
pT4 1 (2) n.a. 
Grade, n (%)   
Papillary, low-grade 15 (26) n.a. 
Papillary, high-grade 23 (41) n.a. 
Invasive, high-grade 19 (33) n.a. 
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1.2. Urine sample collection and processing 
 
Voided urine samples (one per patient) were collected from 22 patients 
with UTUC who were diagnosed and treated between 2006 and 2012 at 
Portuguese Oncology Institute - Porto, Portugal.  
A set of 20 voided urine samples from patients with renal cell carcinoma (n 
= 10), prostate carcinoma (n = 7), and healthy blood donors with no personal or 
family history of cancer (n = 3), were also collected and used for control purposes 
(Table 4). Informed consent was obtained for urine sample collection of patients 
and controls (IRB-CES-IPOFG-EPE 019/08).  
Urine storage and processing conditions were standardized: each sample 
was immediately centrifuged at 4000 rpm for 10 minutes, the pelleted sediment 
was then washed twice with phosphate-buffered saline (PBS), and stored at -80ºC. 
 
Table 4 - Clinical and histopathological parameters of patients with UTUC and 
gender and age distribution of the control set individuals, who provided urine 
samples for this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinicopathological 
features 
UTUC Control Set 
Patients, n 22 20 
Gender, n (%)   
Male 12 (54) 11 (55) 
Female 10 (46) 9 (45) 
Median age, yrs (range) 73 (53 - 86) 61 (48 - 83) 
Grade, n (%)   
Papillary, low-grade  3 (14) n.a. 
Papillary, high-grade  12 (54) n.a. 
Invasive, high-grade  7 (32) n.a. 
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2. Quantitative Methylation Analysis  	  
2.1. Nucleic acids isolation 
 
From each case, a representative paraffin block was selected and an 
experienced uropathologist delimited the area of tumor to be macrodissected. 
Then, a set of 10-20 serial 7-micrometer thick sections were cut and placed on 
glass slides. A disposable sterile scalpel blade was used to macrodissect the 
tumor areas which were subsequently placed in labeled 1,5mL microcentrifuge 
tubes.  
Tissue samples were then deparaffinized using Xilol and Ethanol 100%, 
90%, 70% and 50%, and digested in 1000µL of digestion buffer, composed by 
Tris-HCl 1M, EDTA 0,1M, Tween 20 and sterile bidistilled water (B.Braun, 
Melsungen, Germany), plus proteinase K (20mg/ml, 50µL) (Sigma-Aldrich®, 
Germany), by incubation for 2 to 3 days in a water-bath at 55⁰C, until total 
digestion was accomplished.  
DNA was extracted from tissue and urine samples by the standard phenol-
chloroform procedure [127], using 500 µL of phenol-chloroform solution at pH 8 
(Sigma-Aldrich®, Germany; Merck, Germany) in Phase Lock Gel Light tubes (5 
PRIME, Germany). After centrifuging the tubes for 15 min at 13,000rpm, the 
upper aqueous phase containing DNA was transferred to a new tube, and then 
precipitated at -20⁰C overnight using chilled Ethanol 100% (2 volumes of original 
amount of this phase), Ammonium Acetate 7,5M (1/3 volume) (Sigma-Aldrich®, 
Germany) and glycogen (2µL). This step was followed by two centrifugations at 
13,000rpm for 20 min with 70% ethanol, and the pellets were then air dried and 
eluted in sterile distilled water (B.Braun, Melsungen, Germany). 
 After DNA elution, its concentrations were determined using ND-1000 
Nanodrop (NanoDrop Technologies, Wilmington, USA). 
 
2.2. Sodium Bisulfite Treatment of DNA 
  
The methylation status of a DNA sequence can be determined using 
sodium bisulfite modification-based protocols. Incubation of the target DNA with 
sodium bisulfite results in conversion of unmethylated cytosine residues into 
uracil, leaving the methylated cytosines unchanged (Figure 8).  
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Figure 8. Diagram of bisulfite conversion of unmethylated cytosine, followed 
by PCR. (Adapted from Workflow guide – Epigenetics and DNA Methylation [Applied 
Biosystems]) 
 
This method transforms an epigenetic event into a genetic change, which 
is then able to be analyzed using PCR-based methods. Therefore, bisulfite 
treatment gives rise to different DNA sequences for methylated and 
unmethylated DNA. 
Previously extracted and quantified DNA from 
clinical samples was treated with the EZ DNA 
Methylation-GoldTM Kit (Zymo Research, Orange, CA, 
USA). Before beginning the procedure, we have to 
calculate the DNA volume that we will use, accordingly 
to its concentration and the quantity that we want to 
have (1000ng), and then we have to add sterile distilled 
water to the calculated DNA volume of each sample, 
until we reach the final volume of 20µL. 
Briefly, the procedure comprises (Figure 9): 
bisulfite-mediated conversion of unmethylated 
cytosines, using temperature denaturation 
(thermocycler) to complement chemical denaturation; 
binding of the converted single-stranded DNA to the 
membrane of a spin column; washing; desulfonation of 
membrane-bound DNA; washing of the membrane-
bound DNA to remove desulfonation agent; elution of 
the pure converted DNA from the spin column in 60µL 
Figure 9 - The bisulfite 
conversion procedure using 
EZ DNA methylation GoldTM kit 
(Zymo Research). (Adapted 
from www.zymoresearch.com) 
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of sterile distilled water. Finally, the bisulfite modified DNA was stored at -80⁰C, 
until further use. 
 
2.3. Real-time fluorescence-based methylation-specific PCR  
 
After sodium bisulfite conversion, DNA was used as template for Real-time 
fluorescence-based methylation-specific PCR (qMSP) using locus-specific PCR 
primers and probes, specified in the Appendix I.  
The relative level of methylated DNA for each gene in each sample was 
determined using the following formula: [(target gene/ ACTB (beta-actin) x 1000] 
[128]. Fluorogenic QMSP assays were carried out using Platinum Taq (Invitrogen, 
Carlsbad, CA) for DNA extracted from paraffin-embedded tissues or TaqMan 
Universal PCR Master Mix No AmpErase UNG (Applied Biosystems) for DNA 
extracted from urines in a reaction volume of 20µL, containing 900 nM of 
forward and reverse primers; 200 nM of probe; and 2 µL of bisulfite modified 
DNA as a template, in 96-well plates in an Applied Biosystems 7500 Sequence 
Detector (Perkin Elmer, Foster City, CA). Figure 10 explains the assay principle: 
the 5’ to 3’ nuclease activity of Taq DNA polymerase cleaves the probe and 
releases the reporter, whose fluorescence can be detected by the laser detector 
of the Real-Time PCR System; after crossing a fluorescence detection threshold, 
the PCR amplification results in a fluorescence signal proportional to the amount 
of PCR product generated. 
 
Figure 10. TaqMan technology 
chemistry: A – TaqMan MGB 
probe (with a reporter – R – at the 
5’ end and a quencher at the 3’ 
end – NFQ) specific to the 
sequence anneals to DNA. B – 
During the amplification, DNA 
polymerase (P) is responsible for 
the cleavage of the probe, whose 
reporter emits fluorescence 
detected by Real-Time PCR 
System. (Adapted from TaqMan 
Gene Expression Assay Protocol 
provided by Applied Biosystems) 
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PCR was performed in separate wells for each primer/probe set and each 
sample was run in triplicate. Additionally, multiple water blanks were included as 
negative controls, and six serial dilutions (dilution factor of 5x) of a fully 
methylated bisulfite modified universal DNA control (in vitro methylated human 
DNA, Chemicon) were included in each plate to generate a standard curve.  
A run was considered valid when the slope of each standard curve was 
above - 3.92, corresponding to PCR efficiency of greater than 80%; the R2 of at 
least 4 relevant data points exceeded 0,99; and no amplification in the negative 
controls. To ensure that there was no amplification in the negative controls, the 
water blanks and the standards of each plate were run in a 2% agarose gel 
electrophoresis. 
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3. Cell Culture and Treatment with Epigenetic Modulating Drugs 
 
 To assess the importance of methylation and, possibly, other epigenetic 
mechanisms in the biological development of UTUC, representative transitional 
carcinoma cell lines were selected and exposed to epigenetic modulating drugs. 
The methylation status of the used cell lines was previously determined in the 
prior study [88]. 
Two transitional carcinoma (J82 and TCCSUP) and one squamous 
carcinoma (SCaBER) cell lines were selected for subsequent studies (ATCC – 
American Type Culture Collection, MD, USA). Regarding their methylation status, 
SCaBER was used as a specificity control because it has lower methylation levels 
than transitional cell lines. SCaBER, J82 and TCCSUP cell lines were kindly 
provided by Dr. Sidransky, form Johns Hopkins University, USA. 
All the cell lines were grown in the recommended medium – Eagle’s 
Minimum Essential Medium (MEM) (GIBCO®, Invitrogen, Carlsbad, CA) – and 
supplemented with 10% Fetal Bovine Serum (FBS) (GIBCO®, Invitrogen, Carlsbad, 
CA) and 1% Penicillin-Streptomycin (P-S) (GIBCO®, Invitrogen, Carlsbad, CA). Cell 
lines were subcultured using Trypsin (GIBCO®, Invitrogen, Carlsbad, CA) to 
harvest them as many times as necessary to obtain the desired number of 75 cm3 
cell culture flasks. Several tests for Mycoplasma sp. contamination were 
performed (PCR Mycoplasma Detection Set, Clontech Laboratories, Oxford, UK). 
 
The cell lines were grown until 20 to 30% of confluence was reached in 
75cm3 cell culture flasks. Then, medium containing the corresponding drug(s) - a 
pharmacologic inhibitor of DNMTs, 5-aza-2-deoxycytidine (DAC) (Sigma-Aldrich®, 
Germany) and/or a pan-inhibitor of HDAC, Trichostatin A (TSA) (Sigma-Aldrich®, 
Germany) - was added accordingly. Culture medium and appropriate drug(s) were 
renewed every day according to the schedule represented in Table 5. The mock 
cells served as controls as they were submitted to the medium change procedure 
but were not exposed to any drug. All the treatments were done in triplicate.  
On the fourth day of the treatment schedule, the cells were harvested by 
trypsinization and centrifuged. Then, either pellets were washed in PBS 1x and 
stored at -80oC for RNA extraction, or immediately processed for Protein 
extraction or ChIP analysis. 
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Table 5 - Schedule of cell lines treatment with the epigenetic modulating drugs DAC 
and TSA. 
 
 
 
 
4. Molecular Processing of Drug Exposed Cells 
 
4.1. RNA Extraction  
 
Total RNA was extracted from cell lines pellets using TRIzol® Reagent 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s manual.  
Briefly, pellets were thawed on ice and 1mL of TRIzol® Reagent (Invitrogen, 
Carlsbad, CA, USA) was added. Cells were homogenized using a syringe, and left 
for 5 min at room temperature to ensure the complete dissociation of 
nucleoprotein complexes. Then, all content of the tubes was transferred to 1.5mL 
RNAse-free tubes with 200µL of chloroform (Merck, Germany) previously added, 
vortexed and incubated for 3 min at room temperature, followed by a 
centrifugation for 15 min at 10,600rpm at 4oC. At this point, the mixture 
consisted of a lower red, an interphase and a colorless aqueous phase, where 
RNA remained, so it was collected into a fresh 1.5mL RNAse-free tube placed on 
 0h 24h 48h 72h 
Mock 
15mL 
Medium 
15mL 
Medium 
15mL 
Medium 
Harvest 
1µM DAC 
15mL Medium 
+ 
1.5µL DAC 
15mL Medium 
+ 
1.5µL DAC 
15mL Medium 
+ 
1.5µL DAC 
Harvest 
1µM DAC 
+ 
0.5 µM TSA 
15mL Medium 
+ 
1.5µL DAC 
15mL Medium 
+ 
1.5µL DAC 
15mL Medium 
+ 
1.5µL DAC  
+ 
7.5 µL TSA 
Harvest 
0.5 µM TSA 
15mL 
Medium 
15mL 
Medium 
15mL Medium 
+ 
7.5 µL TSA 
Harvest 
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ice. Next, 500µL of isopropyl alcohol were added to this content, and the tubes 
were placed at room temperature for 10 min to precipitate RNA. Following this, 
tubes were centrifuged for 10 min at 10,600rpm at 4oC and the supernatant was 
carefully eliminated without disturbing the pellet. Finally, 1mL of 75% ethanol was 
added to wash RNA pellets using the vortex followed by one more centrifugation. 
Supernatant was eliminated and the RNA pellets were air-dried until alcohol 
evaporation.  
RNA pellets were eluted, for at least 30 min, in a variable volume of RNA 
Storage Solution (1 mM Sodium Citrate, pH 6.4) (Ambion, Applied Biosystems, 
Foster City, CA, USA) according to pellet size. The eluted RNA was then evaluated 
for concentration and quality using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, USA), and stored at -80oC, until the cDNA synthesis 
procedure.  
 
4.2. cDNA Synthesis 
 
In this step, and using the previous obtained RNA, cDNA was synthetized 
by reverse transcription using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA, USA), according to the manufacturer’s 
instructions.  
Briefly, the following components were added to a RNAse-free PCR tube on 
ice: 1 µg of template RNA, 2 µL of 10x RT Buffer, 0.8 µL of 25x dNTP Mix (100 
mM), 2 µL of 10x RT Random Primers, 1 µL of RNAse Inhibitor, 1 µL of 
MultiScribeTM Reverse Transcriptase, and the appropriate volume of DEPC-treated 
water (deionized, nuclease-free water) (MP Biomedicals LLC, Solon, OH, USA) to 
complete a total volume of 20 µL. The reverse transcription reaction was 
performed in Veriti® Thermal Cycler (Applied Biosystems) during the following 
incubation: 25oC for 10 min, 37oC for 120 min and 85oC for 5 min. The newly 
synthesized cDNA samples were then diluted in 180 µL of DEPC-treated water.  
All this procedure was also applied to Stratagene® QPCR Human Reference 
Total RNA (containing a mixture of RNA from ten different cell lines) (Stratagene, 
La Jolla, CA, USA) that was used as control for the Gene Expression Assays 
described further. In this particular case, cDNA was diluted in 100 µL of DEPC-
treated water, and then stored at -20oC (as the previous samples). 
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4.3. Protein Extraction 
 
Protein extraction from whole-cell lysates was obtained using the Radio 
Immuno Precipitation Assay (RIPA) (Santa Cruz Biotechnology Inc., Santa Cruz, 
CA, USA).  
In brief, the growth medium was removed from the 75cm3 cell culture flask 
by aspiration and the cells were washed with 1x phosphate-buffered saline (PBS) 
to remove residual medium. Then, 300 µL of RIPA buffer (10 µL of PMSF solution, 
10 µL of sodium orthovanadate solution and 20 µL of protease inhibitor cocktail 
solution per mL of 1x RIPA Lysis Buffer) was added, and the flasks were quickly 
scrapped to promote cell lyses and removal. This cell lysate was then transferred 
into a 1.5 mL-tube and incubated for 30 min on ice, following a centrifugation for 
30 min at 13,000 rpm at 4oC. The respective supernatant was then collected into 
a new 1.5 mL-tube. 
Protein concentration was determined using a Pierce BCA Protein Assay Kit 
(Thermo Scientific Inc., Bremen, Germany). The mechanism of action of this assay 
is based on a colorimetric detection and quantitation of total protein by 
bicinchoninic acid (BCA). Protein concentrations were determined with reference 
to standards of bovine serum albumin (BSA). The resulting purple-colored 
reaction product exhibits a strong absorbance at 562 nm, which is nearly linear 
with increasing protein concentrations over a broad working range. A series of 
dilutions of known concentration were prepared from BSA and assayed together 
with our samples.  
In brief, 25 µL of each standard or sample and 200 µL of the working 
reagent (50:1, Reagent A:B) were added to a 1.5 mL-tube and subsequently 
incubated at 37oC for 30 min. The content of the tubes was then transferred into 
a 96-well plate (Ratiolab, Dreieich, Germany) and the absorbance was measured 
at 562 nm on a microplate reader (Fluostar Omega, BMG Labtech, Offenburg, 
Germany). Proteins were then stored at -20oC until further use. 
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5. Quantitative Gene Expression Analysis 
 
cDNA from all cell lines samples was used as the template for real-time 
PCR reaction to quantify the three genes transcripts. The VIM gene expression 
assays (Hs00185584_m1 from Applied Biosystems, Foster City, CA, USA) and the 
endogenous controls assay GUSB and HPRT (Hs99999908_m1 and 
Hs01003267_m1 from Applied Biosystems, Foster City, CA, USA) were used. 
These assays are based on the same technology previously described for qMSP 
assay.  
The GUSB and HPRT assays were used to normalize cDNA input. All 
expression assays were performed separately in 96-well plates in a 7500 
Sequence Detection System (Applied Biosystems, Foster City, CA, USA) according 
to the recommended protocol. Briefly, in each well 9 µL of previously synthesized 
cDNA, 1 µL of Taqman® Gene Expression Assay and 10 µL of Taqman® Gene 
Expression Master Mix (Applied Biosystems) were added. The reactions were 
performed in 96-well plates in a 7500 Real-Time PCR System (Applied Biosystems) 
using the conditions indicated by the manufacturer: 50oC for 2 min, 95oC for 10 
min, 45 cycles at 95oC for 15 sec and 60oC for 1 min. All samples were run in 
triplicate and two negative controls (water blanks) were included in each plate. 
The standard curve method was used for quantitation. cDNA previously 
synthesized from Stratagene® QPCR Human Reference total RNA (Agilent 
Technologies) was used to prepare five consecutive cDNA dilutions (dilution 
factor of 10x) used as standards on each plate. Results were analyzed using the 
Sequence Detector Software version 1.2.3 (Applied Biosystems, Foster City, CA, 
USA). 
The mean quantity of our gene of interest expression levels in each 
sample was normalized against mean quantity of GUSB and HPRT combined 
expression levels (Gene Expression Level= (Gene Mean Quantity / (GUSB & HPRT) 
Mean Quantity)). 
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6. Western-Blot  
 
VIM protein expression was evaluated by Western Blot using a specific 
antibody.  
In short, 30 µg of protein from each cell line were resuspended in loading 
buffer and denatured at 95oC for 5 min. Proteins were then separated by SDS-
PAGE on 10% polyacrylamide gels at 120V at room temperature, and 
subsequently blotted onto Protran nitrocellulose transfer membranes (Whatman, 
Dassel, Germany) at 50V for 1h at 4oC. After electroblotting, the membranes were 
incubated in blocking buffer [3% bovine serum albumin (BSA) in Tris-buffered 
saline containing 0.1% Tween 20 (TBST)] for 3h at room temperature with 
agitation. The membranes were then incubated overnight at 4oC with the primary 
monoclonal mouse antibody for VIM (Dako, Denmark) diluted 1:750 in blocking 
buffer. After three washing steps with TBST, the membranes were incubated for 
1h at room temperature with a horseradish peroxidase conjugated secondary 
anti-mouse antibody (Bio-Rad, München, Germany) diluted 1:3000 in blocking 
buffer. After washing with TBST, the membranes were developed using Immun-
Star WesternC Chemiluminescent Kit (Bio-Rad) and exposed to Amersham 
Hyperfilm (GE Healthcare). 
To ensure equal loading of protein, the membranes were stripped and 
reprobed with an antibody against the loading control (ACTB). The membranes 
were incubated at room temperature for 15 min with 20 mL of EzWay Antibody 
Erasing Buffer (Koma Biotech, Seoul, Korea) under vigorous shaking, followed by 
at least 5 washes with bidistilled water (B. Braun).  
After this step, membranes were incubated with a monoclonal mouse 
antibody against ACTB (Sigma-Aldrich) diluted 1:8000 in blocking buffer (5% 
nonfat dry milk in TBST) for 30 min at room temperature. After 3 x washing, the 
membranes were then incubated for 15 min at room temperature with a 
horseradish peroxidase conjugated secondary anti-mouse antibody (Bio-Rad) 
diluted 1:3000 in blocking buffer. 
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7. Chromatin Immunoprecipitation  
 
A chromatin immunoprecipitation assay (ChIP) was performed using EZ-
Magna ChIPTM G – One-Day Chromatin Immunoprecipitation Kit (Millipore, MA, 
USA) according to manufacturer’s instructions, using the previously mentioned 
J82 cell line, after treatment with epigenetic modulating drugs. This ChIP 
procedure may be divided into 5 important steps, as we may see in Figure 11.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Five steps summary of chromatin immunoprecipitation (ChIP) 
methodology: (A) in vivo crosslinking and lysis, (B) sonication to shear DNA, (C) 
immunoprecipitation of crosslinked protein/DNA, (D) reverse crosslink of protein/DNA 
complexes to free DNA and its purification, and (E) example of an analysis of a gene ChIP 
enrichment by real-time quantitative PCR. (Adapted from [129]) 
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On the first step – in vivo crosslinking and lysis - formaldehyde was added 
to each cell culture flask until a final concentration of 1% was reached, and 
incubated for 10 min at room temperature. Next, 2mL of 10x glycine were added 
in each flask in order to quench unreacted formaldehyde, and after a 5 min 
incubation at room temperature, flasks were placed on ice. Then, culture medium 
was carefully removed and cells were 2 x washed with 20mL of cold 1x PBS. 
Finally, cells were scrapped and resuspended into tubes containing 2mL of cold 
1x PBS and 1x Protease Inhibitor Cocktail II (PIC), which were then centrifuged to 
pellet the cells, and remove supernatant. Cells were then putted on ice for 15min 
after being resuspended in 0.5mL of 1x Cell Lysis Buffer and 1x PIC, with vortex 
shaking every 5 min. Tubes were centrifuged again (800 x g for 5 min, at 4oC), 
supernatant was removed and 0.5mL of 1x Nuclear Lysis Buffer and 1x PIC were 
added to resuspend the pellet.  
At this time, sonication is needed do shear the DNA. This step was 
performed for 20 min, using 300µL of resuspended pellet, on iced water with a 
Bioruptor® Standard (Diagenode, Philadelphia, PA, USA), and with cycles of 20 sec 
with sonication ON, followed by 50 sec with sonication OFF. Sonicated chromatin 
was stored into 50µL aliquots at -80oC, until further use. 
After this, and in order to validate the sonication performance, 5µL of 
sonicated chromatin were incubated at 37oC for 30 min, with 10µg of RNase 
(Sigma-Aldrich, Germany), following an addition of 1µL of Proteinase K and 
incubation at 62oC for 2h. After that, the respective sample was loaded into a 2% 
agarose gel and runned for 1h at 140V, and was observed in an ultraviolet 
transilluminator [Pharmacia Biotech ImageMaster VDS (Pharmacia Biotech, Bay 
Area)]. 
The third step of ChIP procedure is the immunoprecipitation of crosslinked 
protein/DNA. Each 50µL aliquot of sonicated chromatin was diluted in 450µL 1x 
Dilution Buffer and 2.25µL 1x PIC, into a new tube. To prepare the input control, 
5µL of this solution was reserved into a new tube, and reserved at 4oC until 
elution of protein/DNA complexes and reverse crosslink of protein/DNA 
complexes to free DNA, as described below. 
Afterwards, to each tube of the previously made solution were added, 
separately, 10µL of anti-H2A.Z (ab4174, Abcam, Cambridge, UK), 10µL of anti- 
AcH2A.Z (ab18262, Abcam, Cambridge, UK), 5µL of anti-H3 (ab1791, Abcam, 
Cambridge, UK), 5µL of anti-AcH3 (06-599, Millipore, MA, USA), 5µL of anti- 
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H3K4me3 (ab8580, Abcam, Cambridge, UK), 5µL of anti-H3K27me3 (07-499, 
Millipore, MA, USA), 5µL of anti-H3K9me3 (07-442, Millipore, MA, USA), 5µL of 
anti-H3K36me2 (ab9049, Abcam, Cambridge, UK), 5µL of anti-H4 (ab70701, 
Abcam, Cambridge, UK), 5µL of anti-H4K20me3 (ab9053-100, Abcam, Cambridge, 
UK), 1µL of the positive control anti-RNA Polymerase II and 1µL of the negative 
control Normal Mouse IgG, the last two provided with the kit. After, 20µL of fully 
suspended protein G magnetic beads were added to the tubes, which were then 
incubated overnight with rotation, at 4oC. 
On the next day, protein G magnetic beads were pelleted using a magnetic 
separator (Magma Grip Rack) (Millipore, MA, USA) and the supernatant was 
removed. After that, beads were fully resuspended and washed for 5 min, with 
constant rotation, with four different buffers in the following order: 
1st. Low Salt immune Complex Wash Buffer;  
2nd. High Salt Immune Complex Wash Buffer;  
3rd. LiCl Immune Complex Wash Buffer; 
4th. TE Buffer. 
To each tube were added 100µL of ChIP Elution Buffer and 1µL of 
Proteinase K, following incubation for 2h at 62oC, with permanent shaking. 
Hereinafter, a 95oC incubatation during 10min was performed, and tubes were 
allowed to cool until they reached room temperature. Beads were separated using 
the magnetic separator and the supernatant was reserved into fresh microfuge 
tubes. 
For each immunoprecipitation, 500µL of Bind Reagent “A” were added to a 
Spin Filter within a Collection Tube. Tubes were then centrifuged at 12,600 x g 
for 30 seconds, and the eluate was discarded (both filter and collection tube were 
saved). Next, the same process was repeated, this time with Wash Reagent “B”. 
Finally, the Spin Filter was put into a fresh collection tube, 50 µL of Elution Buffer 
“C” were added directly onto the center of the white Spin Filter Membrane and a 
new centrifugation was performed (12,600 x g for 30 seconds). The Spin Filter 
was discarded and the Collection Tube containing the purified DNA was stored at 
-20oC until further use. 
At this point, DNA was ready for real-time quantitative PCR. This later was 
performed in order to analyze the specific prost-translational histone marks 
nearby VIM gene promoters. Therefore three pairs of primers were designed for 
VIM gene, being the primers “A” those closer to the TSS and primers “C” those 
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that were farthest from the TSS. Information about the primers used is compelled 
in Table 6. About this, it is important to mention that, until now, we couldn’t be 
able to optimize the second pair of primers, the “B” pair.  
 
Table 6 – ChIP qRT-PCR primers features: sequence, distance from TSS and annealing 
temperature. 
* Lack optimization 
 
The assays were performed separately in 96-well plates in 7500 Real Time 
PCR System (Applied Biosystems, Foster City, CA, USA), according to the 
recommended protocol. Briefly, in each well 2µL of sonicated chromatin, 10µL of 
Power SYBR® Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 
0.25µL (Primers “A”) or 0.5µL (Primers “C”) of primers solution (forward + reverse) 
(10mM) and 7.75µL or 7.5µL(respectively) of DEPC-treated water were added. PCR 
conditions were those previously defined by manufacturer: 50oC for 2min, 95oC 
for 10min, 45 cycles at 95oC for 15sec and 60oC for 1min, 95oC for 15sec, 60oC 
for 20sec and, finally, 95oC for 15 sec. 
All samples were run in triplicate and multiple water blanks were added to 
each plate as negative controls. 
The results were analyzed using the 7500 Software for 7500 and 7500 
Fast Real Time PCR Systems V2.0.6 (Applied Biosystems, Foster City, CA, USA). A 
run was considered valid under conditions previously described. Data 
normalization was conducted using the Input Percent Method, meaning that 
signals obtained from ChIP samples were divided by signals obtained from the 
input sample, the last one representing the amount of chromatin used for 
immunoprecipitation. The enrichment over the core histone (H3, H4 or H2A.Z) 
was then calculated for each histone mark. 
 
Gene Primer Sequence Distance 
from TSS 
T
anneling
 
(oC) 
VIM 
A 
Forward 5’ tagtgagcaggagaaagcacag 3’ 
398bp 60 
Reverse 5’ aaagacaggacatggaggatgt 3’ 
B 
Forward 5’ cactatgttggctcactgcaac 3’ 
785bp n/a* 
Reverse 5’ acttgaggtcaggagttcgaga 3’ 
C 
Forward 5’ ctgaactgatacagtggcaagtga 3’ 
1268bp 60 
Reverse 5’ tcaggatatgcatgccaaag 3’ 
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8. Statistical Analysis  
 
The frequency, median and interquartile range of GDF15, TMEFF2 and VIM 
promoter methylation levels of normal tissue/control samples and UTUC 
tissue/urine samples were determined.  
To categorize samples as methylated or unmethylated, a cutoff value was 
chosen based on the highest methylation ratio value obtained for the respective 
normal/control samples, ensuring perfect specificity of the assay.  
The nonparametric Mann-Whitney U-test assessed differences in 
quantitative methylation values. Relationships between methylation ratios and 
gender, grade, and pathological stage were evaluated using the Mann-Whitney 
and Kruskall-Wallis tests, as applicable. Spearman nonparametric correlation test 
was performed to assess the association between age and methylation levels.  
Specificity, sensitivity, positive predictive value (PPV), negative predictive 
value (NPV) and accuracy of the three-gene panel as a UTUC biomarker were 
determined. A receiver operator characteristics (ROC) curve was constructed by 
plotting the true positive (sensitivity) against the false-positive (1-specificity) rate, 
and the area under de curve (AUC) was calculated.  
Differences in proportions test was performed to compare the diagnostic 
performance of methylation analysis compared to urine cytology.  
Disease-specific survival curves (Kaplan–Meier with log rank test) were 
computed for standard variables (tumor stage and grade) and for categorized 
methylation status. A Cox-regression model comprising all significant variables 
(multivariable model) was computed to assess the relative contribution of each 
variable to the follow-up status. For multivariable testing, pathological stage and 
age were recoded into two groups (Ta–T1 versus T2–4; lower than 75 years 
versus higher than 75 years).  
In cell lines, differences in VIM transcript as well as in histone marks levels 
among the treatments performed were determined using a One-Way Analysis of 
Variance (one-Way ANOVA) test, followed by a multiple comparison Dunnett’s 
test, comparing all groups against the Mock. 
Two-tailed P-values were derived from statistical tests, using a computer-
assisted program (SPSS Version 20.0, Chicago, IL), and results were considered 
statistically significant at P < 0.05, with Bonferroni´s correction for multiple tests, 
when applicable. 
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RESULTS 
 
1. Methylation analysis of UTUC tissues and performance of the 
methylation panel in urines 
 
1.1. Tissue samples analysis 	  
The majority of UTUC tissue samples were methylated at GDF15, TMEFF2 
and VIM promoters, and relative methylation levels were significantly higher when 
compared to normal urothelium (P = 0.022; P < 0.001; P < 0.001, respectively) 
(Figure 12 and Table 7).  
 
 
 
 
 
 
 
 
 
 
Figure 12. Box-plots of (A) GDF15, (B) TMEFF2 and (C) VIM promoter 
methylation levels across both normal upper tract urothelium (NUTU) and upper tract 
urothelial carcinoma (UTUC) tissues (*Mann-Whitney U Test). 
 
 
 
Table 7 - Frequency and distribution of promoter methylation levels in normal upper 
tract urothelium (NUTU) and upper tract urothelial carcinoma (UTUC) tissue samples 
measured by qMSP. 
 
Gene  NUTU, n NUTU med (IQR) UTUC, n UTUC med (IQR) P value* 
GDF15 0/36 24.89 (10.95 - 48.85) 32/57 252.74 (0.0 - 481.78) 0.022 
TMEFF2 0/36 0.0 (0.0 - 0.0) 26/57 0.0 (0.0 - 123.49) <0.001 
VIM 0/36 0.0 (0.0 - 0.0) 54/57 220.25 (126.69 - 438.67) <0.001 
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1.2. Urine samples analysis 
 
The three-gene panel was then tested in a set of urine sediments from 22 
UTUC patients and a mix of 20 subjects not carrying UTUC (controls). Methylation 
levels in UTUC urines were significantly higher than those of controls, for all 
genes (Table 8). 
 
Table 8 - Frequency and distribution of promoter methylation levels in normal upper 
tract urothelium (NUTU) and upper tract urothelial carcinoma (UTUC) tissue samples 
measured by qMSP. 
 
1.3. Biomarker Performance 
 
The combined assessment of promoter-methylation of GDF15, TMEFF2 and 
VIM allowed for discrimination of UTUC tissue samples from normal mucosa with 
100% sensitivity and specificity, providing full diagnostic coverage (Table 9). 
These results were confirmed by ROC curve analysis, with an AUC of 1.000 [95% 
confidence interval (CI): 0.998 - 1.000, P < 0.001] (Figure 13B). Notably, the gene 
panel identified UTUC in urine with 91% sensitivity and 100% specificity. ROC 
curve analysis depicted an AUC of 0.923 [95% CI: 0.819 - 1.000, P < 0.001] 
(Figure 13C). 
  
Table 9 - Performance of epigenetic biomarkers for the detection of upper tract 
urothelial carcinoma in tissue and urine sediments. 
Gene  Control, n Control med (IQR) UTUC, n UTUC med (IQR) P value* 
GDF15 0/20 0.0 (0.0 - 0.0) 17/22 3.79 (0.09 - 21.67) <0.001 
TMEFF2 0/20 0.0 (0.0 - 0.0) 15/22 6.33 (0.0 - 57.22) 0.001 
VIM 0/20 0.0 (0.0 - 0.0) 18/22 31.28 (11.07 - 145.81) <0.001 
 
Sensitivity 
% (n positive 
/ n total) 
Specificity 
% (n negative / 
n total) 
PPV 
% 
NPV 
% 
Accuracy 
% 
Tissue samples      
VIM 95 (54/57) 100 (36/36) 100 92 97 
VIM / GDF15 98 (56/57) 100 (36/36) 100 97 99 
VIM / GDF15 / TMEFF2 100 (57/57) 100 (36/36) 100 100 100 
Urine samples       
VIM 82 (18/22) 100 (20/20) 100 83 91 
VIM / GDF15 91 (20/22) 100 (20/20) 100 91 95 
VIM / GDF15 / TMEFF2 91 (20/22) 100 (20/20) 100 91 95 
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Figure 13. Receiver operating characteristic curve in upper tract urothelial 
carcinoma (UTUC) for each individual gene (GDF15, TMEFF2, and VIM) in tissues (A), and 
the combination of three genes (GDF15, TMEFF2, and VIM) in tissues (B), and in urines (C). 
 
 
To ascertain the clinical usefulness of the methylation assay, its 
performance was compared with cytological diagnosis performed by an 
experienced cytopathologist, in 19 cases. Remarkably, the proportion of true 
positive cases using the panel of methylated genes was significantly higher than 
that of cytology (P < 0.001; Figure 14). Of 19 cases analyzed, only five were 
cytologically diagnosed as malignant, six as negative for malignancy, and eight 
were rendered as “inconclusive/suspicious for malignancy”, corresponding to an 
overall sensitivity of only 26% (Table 10). Strikingly, the gene panel correctly 
identified 17 cases as malignant (89% sensitivity), whereas the remaining two 
cases were also cytologically diagnosed as negative. 
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Figure 14.  Pie charts representing the diagnostic test sensitivity for the 
methylated gene panel - GDF15, TMEFF2, and VIM  (A) and cytology (B), performed in 
urine samples from the same patients (n = 19) diagnosed with upper tract urothelial 
carcinoma. (*Differences in Proportions Test). 
 
 
 
 
 
 
 
 
 
Table 10 - Comparison between results of methylated gene panel and cytology tests 
across urine samples from the same patient. A green, yellow or red box, indicate a 
positive, inconclusive or negative result, respectively. 
 
	  
Methylation	  Assay	   Cytology	  
#1	   	  	   	  	  
#2	   	  	   	  	  
#3	   	  	   	  	  
#4	   	  	   	  	  
#5	   	  	   	  	  
#6	   	  	   	  	  
#7	   	  	   	  	  
#8	   	  	   	  	  
#9	   	  	   	  	  
#10	   	  	   	  	  
#11	   	  	   	  	  
#12	   	  	   	  	  
#13	   	  	   	  	  
#14	   	  	   	  	  
#15	   	  	   	  	  
#16	   	  	   	  	  
#17	   	  	   	  	  
#18	   	  	   	  	  
#19	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2. Association between quantitative promoter methylation and 
clinicopathological parameters and survival analyses 
 
No association was disclosed between GDF15, TMEFF2 and VIM promoter 
methylation and patient’s gender or pathological stage. A significant association 
was found for GDF15 methylation levels and age in UTUC patients (R = 0.303, P = 
0.022), but not in controls. Additionally, a significant association of VIM 
methylation levels and higher tumor grade (P = 0.015) was found, and VIM 
methylation levels differed between papillary high-grade and invasive UTUC (P = 
0.006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Disease-specific survival according to clinicopathological parameters 
[histopathological classification (A) and pathological stage (B)] and VIM promoter 
methylation status (C). 
 
Of the 57 UTUC patients one was lost for follow-up. The median follow-up 
was 31 months (range: 1–146 months). At the time of the last follow-up, 23 
patients were alive with no evidence of cancer, 9 patients were alive with cancer 
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progression, and 24 patients had deceased, 19 of which due to UTUC. For the 
purpose of survival analyses, all cases were coded based on gene methylation 
levels using the median value as cutoff. Disease-specific survival analysis showed 
that patients with low VIM promoter methylation levels had a significantly shorter 
overall survival (P = 0.013; Figure 15C), and a 3.3-fold increased hazard ratio (P = 
0.019; Table 11). The same was not observed for GDF15 and TMEFF2 promoter 
methylation, thus we only further analyzed VIM methylation.  
A poor outcome was depicted for patients with higher grade and 
pathological stage (Figure 15A and 15B; P = 0.03 and P = 0.04, respectively). In 
univariate Cox-regression analysis, both histopathological type and pathological 
stage, but not age or gender, carried prognostic information (P = 0.025 and P = 
0.049; Table 11). When clinical and epigenetic variables were introduced in a 
Cox-regression model for disease-specific survival, pathological stage and VIM 
methylation status were selected in the final model as independent predictors of 
outcome. After patients were categorized according to pathological stage, low 
VIM methylation levels carried a 18-fold increased risk of cancer-related death 
(95% CI: 3.24–99.25, P < 0.001) in the advanced disease group (pT2-4). Disease-
free survival analysis did not disclose any significant association. 
 
Table 11 - Cox regression models assessing the potential of clinical and epigenetic 
variables in the prediction of disease-specific survival for 56 upper tract urothelial 
carcinoma (UTUC) patients (PLG, papillary low-grade; PHG, papillary high-grade; IHG, 
invasive high-grade) 
Disease-specific 
Survival 
Variables 
Hazard 
Ratio (HR) 
95% CI* for OR P 
Univariate pTNM 2.81 (1.01 - 7.83) 0.049 
 
Grade 
PLG vs. PHG 1.79 (0.45 - 7.17) 0.411 
 PLG vs. IHG 4.41 (1.21 - 16.11) 0.025 
 Age 1.93 (0.69 - 5.40) 0.208 
 Gender 0.36 (0.11 - 1.23) 0.104 
 VIM methylation ≤ median 3.26 (1.22 - 8.73) 0.019 
Multivariate pTNM 3.78 (1.18 - 12.07) 0.025 
 
Grade 
PLG vs. PHG 
2.51 (0.60 - 10.56) 0.209 
 PLG vs. IHG 3.02 (0.79 - 11.53) 0.106 
 VIM methylation ≤ median 5.97 (1.81 - 19.64) 0.003 
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3. Influence of the action of Epigenetic Modulating Drugs in VIM 
transcript and protein levels 
 
3.1. Association between VIM Transcript and Promoter Methylation 
Levels, after the Action of Epigenetic Modulating Drugs 
 
Given the previous results in patient’s samples, we decided to investigate 
VIM specific role in the carcinogenesis of UTUC, using in vitro models for that 
purpose. 
Previously, we have demonstrated that cell lines’ exposure to DAC and/or 
TSA reduced methylation levels (data not shown) [88], however no assessment of 
VIM transcript levels has been yet performed. Thus, two transitional carcinoma 
cell lines (J82, TCCSUP) and one squamous cell carcinoma cell line (SCaBER) were 
exposed to these drugs, either alone or in combination, and expression levels 
were determined. 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Transcript levels of VIM in J82, TCCSUP and SCaBER cell lines after 
exposure to the epigenetic modulating drugs DAC and/or TSA. The results are 
presented in fold variation in comparison to the experimental control. (Dunnett Test, 
***p< 0.001) 
 
As depicted in Figure 16, 1µM DAC exposure significantly increased VIM 
transcript levels in all the three cell lines (p < 0.001). The combined treatment 
with DAC and TSA also significantly increased VIM expression levels in TCCSUP 
and SCaBER cell lines (p < 0.001). Moreover, cell lines treated with TSA alone did 
not show any variation of VIM transcript levels, comparing with untreated cells.   
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3.2. Influence of Epigenetic Modulating Drugs in VIM Protein Levels 
 
To confirm the impact of DAC on VIM re-expression in J82, TCCSUP and 
SCaBER cell lines, the respective protein levels were also assessed by Western 
Blot. Similarly to transcript levels, VIM protein levels significantly increased in all 
cell lines after DAC exposure, alone and in combination with TSA (Figure 17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. VIM protein expression analysis by Western Blot in (A) J82, (B) 
TCCSUP and (C) SCaBER cell lines exposed to epigenetic modulating drugs DAC and 
TSA. The picture is representative of three independent experiments. 
 
 
Surprisingly, VIM protein levels in SCaBER cells (Figure 17C) treated with 
TSA (0.5µM concentration) seem to have increased significantly, following the 
opposite trend of the respective transcript levels. 
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4. Chromatin Immunoprecipitation Analysis 
 
After treatment with epigenetic modulating drugs DAC and TSA, ChIP was 
performed in J82 cell line. At this point, it is only worth continuing using the 
transitional carcinoma cell lines, because it is our biological model of interest, 
and SCaBER cells are no longer needed as a methylation/expression control. 
TCCSUP ChIP results were not obtained at this time. 
 
Chromatin of treated cell lines was immunoprecipitated for several 
transcriptional activating histone marks (acH2A.Z, acH3, H3K36me2 and 
H3K4me3) and repression histone marks (H3K27me3, H3K9me3 and H4K20me3). 
Immunoprecipitation for H2A.Z, H3 and H4 was also performed. After ChIP, qRT-
PCR was carried out to evaluate accumulation of marks along the VIM promoter 
region.  
Primarily, we observed that DAC exposure increased H3, H4 and H2A.Z 
deposition across VIM promoter, and more specifically, the combined treatment 
seemed to be crucial in the enrichment of the above-mentioned histones at 
nucleosomes distant from the TSS (Figure 18 A, G and I). Furthermore, H4 and 
H2A.Z were practically absent in J82 untreated cells, whereas increased levels of 
these histones were found after cells exposure to epigenetic modulating drugs, 
especially upon exposure to combined drugs.   
Interestingly, both H3K27me3, H3K9me3 and acH2A.Z levels were barely 
detectable on mock and drug treated cells, suggesting that this marks do not 
exist across VIM promoter (Figure 18 D, E and J). 
Concerning H3 activation marks, acH3, H3K4me3 and H3K36me2, an 
increase was observed in nucleosomes distant to the TSS after the combined DAC 
and TSA exposure (Figure 18 B, C and F). 
Contrarily, the deposition of the repressive mark H4K20me3 dramatically 
decreased after drugs exposure, across the entire VIM promoter (Figure 18H).  
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Figure 18. ChIP results for J82 cell line concerning (A) H3, (B) acH3, (C) 
H3K4me3, (D) H3K27me3, (E) H3K9me3, (F) H3K36me2, (G) H4, (H) H4K20me3, (I) 
H2A.Z and (J) acH2A.Z histones and histones marks across VIM promoter. Results are 
normalized with the input of total sonicated chromatin. (Dunnett’s Test, *p < 0.002) 
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DISCUSSION 
 
 
UTUCs are clinically aggressive neoplasms (60% are invasive at diagnosis, 
compared to 15-20% for bladder UCC), mostly due to late diagnosis, as UTUC is 
usually silent at its earliest stages and difficult to detect using ultrasonography 
and urine cytology. Thus, the development of novel, cost-effective and non-
invasive methods for accurate diagnosis of UTUC are likely to have a significant 
impact in patient management. Gene promoter methylation, a cancer hallmark, 
has shown promise for accurate detection of urological cancers (especially those 
of the prostate and bladder) and may thus be of clinical usefulness [130]. We 
have recently identified a panel of markers (GDF15, TMEFF2 and VIM 
methylation), which detects bladder UCC with high sensitivity and specificity, 
both in tissue and urine [88]. Owing to the morphological and genomic 
similarities with UTUC [125], we hypothesized that the same gene panel might 
show a comparable performance. 
 
Remarkably, this panel identified UTUC with 100% and 91% sensitivity in 
tissue and urine samples, respectively, maintaining perfect specificity in both. 
These results constitute a significant step forward in the detection of UTUC and 
provide a basis for the development of an assay to be used in clinical practice. In 
fact, owing to the difficult accessibility of the UUT, current methods used to 
detect a neoplasm in this anatomical location are mostly ineffective. Indeed, our 
study demonstrates that urine cytology may hardly be considered a diagnostic 
modality since it only allowed for the diagnosis of 26% of cases. Although higher 
sensitivity has been reported elsewhere, reaching 40% [131], cases diagnosed by 
cytology are usually muscle-invasive, thus carrying an unfavorable prognosis 
[131, 132].  
On the other hand, high specificity is also very important because most of 
individuals to which this test might be offered are not carriers of UTUC, and thus, 
the requirement for other procedures to confirm an abnormal result of the test, 
most of which would be invasive, has to be minimized. Finally, it should be 
emphasized that this gene panel is able to discriminate UCC from renal cell 
carcinoma, confirming another previous observations made by our group [133], 
thus providing valuable information for cases in which ultrasonography is unable 
to discriminate tumors of renal pelvic from renal parenchymal origin. The 
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purpose of including renal cell tumors, as well as prostate cancer, as controls in 
urine samples was to demonstrate the tumor-specificity of the gene panel. 
Indeed, UTUC, renal cell tumors and prostate carcinoma are amenable to 
detection in urine samples and occur in similar age spectra. Thus, it would be 
important for this gene methylation test to accurately predict urothelial 
carcinoma, discriminating from other common tumors of the genitourinary tract. 
 
Interestingly, survival analysis showed that low VIM promoter methylation 
levels independently predict poor disease-specific survival in UTUC patients, 
particularly those with high-stage disease. Thus, the gene panel is able to convey 
not only diagnostic, but also, prognostically important information. Because 
detection of UTUC based on GDF15, TMEFF2 and VIM relies on the identification 
of higher promoter methylation levels in UCC compared to normal urothelium, 
the association of low VIM promoter methylation levels with worse prognosis 
might seem paradoxical. However, it should be recalled that VIM encodes for 
vimentin, an intermediate filament characteristic of cells with mesenchymal 
phenotype, not expressed in most normal epithelia (including urothelium) neither 
in most carcinomas [134]. However, VIM de-novo expression or overexpression 
has been reported in various epithelial cancers, including those of prostate [135], 
breast [136] and lung [137], associating with increased tumor growth, invasion 
and poor prognosis. In these instances, vimentin expression has been associated 
with epithelial to mesenchymal transition (EMT), a biological process that is 
associated with an invasive phenotype [134]. Thus, we speculate that during early 
UUT carcinogenesis, the VIM promoter is progressively methylated and the gene 
is kept silenced, as in normal urothelium, whereas in a subset of UTUC, 
methylation is decreased, allowing for aberrant vimentin expression, due to 
stimuli leading to EMT. As a consequence, these tumors would be more prone to 
local invasion and systemic dissemination, thus fostering disease progression 
and reducing disease-specific survival. 
 
One of the major limitations of our study consists on the relatively small 
number of cases analyzed. However, it should be noted that UTUC is a relatively 
uncommon neoplasm and we report on the casuistic of a single-center. This also 
justifies the fact that in only 19 cases we had information on the cytological 
diagnosis, which corresponds to the cases diagnosed more recently during the 
collection period of this study. Thus, a larger and, ideally, multicenter study, 
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should be performed to validate our findings. Moreover, this gene panel is unable 
to discriminate upper from lower urinary tract UCC. Thus, only after exclusion of 
bladder and urethral UCC should a diagnosis of UTUC be considered following a 
positive test. However, owing to the similarities between UTUC and lower urinary 
tract UCC, the identification of specific markers is difficult. Some studies 
proposed that microsatellite instability [123], CDH1 [138], and FXYD3 gene 
expression [139] might provide such discrimination but none has been replicated 
by other research teams, yet. Thus, positive testing would require additional 
work-up of the urinary tract. 
 
Additionally, we investigated whether this gene is epigenetically regulated 
in urothelial carcinomas.  
As expected, VIM transcription levels increased significantly after exposure 
to DAC, a DNMTs inhibitor, i.e. a demethylation agent, in both tested transitional 
carcinoma cell lines. These results compare well with those of methylation 
obtained previously for the same cell lines [88]. Moreover, protein levels of VIM 
also followed the same trend as observed for transcript levels for same treatment 
conditions. Importantly, the increased transcript levels were corroborated by ChIP 
assay results, which demonstrated an increase in histone activating marks, such 
as acH3, H3K4me3 and H3K36me2 far from the TSS, after DAC and TSA 
exposure, with concomitant decrease of the repressive histone mark H4K20me3 
[140]. Moreover, regarding acH2AZ low deposition across the TSS, our results are 
in accordance with previous studies on PCa cell lines, in which genes highly 
methylated displayed lower levels of this mark, whereas a gain of acH2AZ mark 
was associated with gene activation in cells lines treated with epigenetic 
modulating drugs [141]. Therefore, our results suggest that epigenetic 
modulating drugs are able to induce VIM re-expression. 
Bringing together our data, we can postulate that epigenetic mechanisms 
are responsible of VIM deregulation in urothelial carcinomas. However, it is 
important to replicate these same results in other transitional carcinoma cell lines 
to assure its validity.   
 
 
 
 
 
	  	  	  	   72	  
CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 
The molecular characterization and the management of UCs and UTUCs 
have progressed considerably in the past few years. The identification of the 
different mechanisms of carcinogenesis in UCs of the bladder and of the UUT has 
incited many researchers to focus on this issue. Moreover, the development of 
novel diagnostic and prognostic biomarkers for UTUC, which might allow for its 
identification, is required to provide a non-invasive, specific and sensitive 
method, easy to perform, and cost-effective. 
In this thesis we were able to demonstrate that GDF15, TMEFF2 and VIM 
promoter methylation accurately discriminates UTUC from normal urothelium, 
prostate and renal cell carcinoma, both in tissue and urine samples. Furthermore, 
low VIM methylation levels predicted poor prognosis, especially in high-stage 
disease. Thus, this gene panel may assist in the clinical management of UTUC 
patients. 
Importantly, we also showed that VIM expression is epigenetically 
regulated in urothelial carcinoma.  
 
To ascertain the utility of VIM expression in clinical samples and to clarify 
how VIM epigenetic deregulation affects urothelial cells’ neoplastic 
transformation, we need to perform additional tasks, specifically: 
 
 
 
⇒ Perform immunohistochemical analysis in the series of UTUC 
tissues; 
⇒ Induction of VIM expression on methylated transitional carcinoma 
cell lines using a full-length human VIM cDNA clone; 
⇒ Perform functional assays on the transfected cells: cell viability, 
apoptosis and invasion assays; 
⇒ Accomplish in vivo studies of tumors’ formation.  
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APPENDIX I 
 
Sequences of the primers and probes used in the quantitative methylation-
specific PCR experiments, with sizes and amplicons generated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Set Sequence 
Product 
size, bp 
T
Annealing
  
ºC 
ACTB_QMSP 
Forward Primer 5’ TGG TGA TGG AGG AGG TTT AGT AAG T 3’ 
133 60 Reverse Primer 5’ AAC CAA TAA AAC CTA CTC CTC CCT TAA 3’ 
Probe FAM 5' ACC ACC ACC CAA CAC ACA ATA ACA AAC ACA 3' TAMRA 
GDF15_QMSP 
Forward Primer 5’ TCG GCG GTT ATT TGT ATT TGC 3’ 
101 60 Reverse Primer 5’ CGT CGA AAA CAA CCG AAA CA 3’ 
Probe 5' FAM - TTT TCG AGG TTT TTC G - MGB 3' 
TMEFF2_QMSP 
Forward Primer 5’ GTT CGG GGT TAC GCG C 3’ 
83 60 Reverse Primer 5’ TTC GCC TCA CTC TCC GCT 3’ 
Probe 5' FAM - TCG GAT TTC GTT TTC GGT AG - MGB 3' 
VIM_QMSP 
Forward Primer 5’ TTC GGG AGT TAG TTC GCG TT 3’ 
108 60 Reverse Primer 5’ ACC GCC GAA CAT CCT ACG A 3’ 
Probe 5' FAM - TCG TCG TTT AGG TTA TCG T - MGB 3' 
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